Clustering of conformational IgE epitopes on the major dog allergen Can f

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Curin, Mirela ^a   Weber, Milena ^a   Hofer, Gerhard ^b   Apostolovic, Danijela ^c   Keller, Walter ^b   Reininger, Renate ^d   Swoboda, Ines ^a,e   Spitzauer, Susanne ^d   Focke Tejkl, Margit ^a   Van Hage, Marianne ^c   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF APPLIED SCIENCES   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALLERGEN CAN F I; EPITOPE; IMMUNOGLOBULIN E;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DOG; EPITOPE MAPPING; HUMAN; IMMUNOLOGY; LEPORIDAE; PROTEIN CONFORMATION;

ALLERGENS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; DOGS; EPITOPE MAPPING; EPITOPES; HUMANS; IMMUNOGLOBULIN E; PROTEIN CONFORMATION; RABBITS;

EID: 85029762954     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-11672-5     Document Type: Article

References (46)

1. Konradsen, J. R. et al. Allergy to furry animals: New insights, diagnostic approaches, and challenges. J Allergy Clin Immunol. 135, 616-25 (2015).
2. Nilsson, O. B., van Hage, M. & Grönlund, H. Mammalian-derived respiratory allergens-implications for diagnosis and therapy of individuals allergic to furry animals. Methods 66, 86-95 (2014).
3. Berge, M., Munir, A. K. & Dreborg, S. Concentrations of cat (Fel d1), dog (Can f1) and mite (Der f 1 and Der p1) allergens in the clothing and school environment of Swedish schoolchildren with and without pets at home. Pediatr Allergy Immunol 9, 25-30 (1998).
4. Arlian, L. G., Neal, J. S., Morgan, M. S., Rapp, C. M. & Clobes, A. L. Distribution and removal of cat, dog and mite allergens on smooth surfaces in homes with and without pets. Ann Allergy Asthma Immunol 87, 296-302 (2001).
5. Burbach, G. J. et al. GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy 64, 1507-15 (2009).
6. Schmitz, R., Ellert, U., Kalcklösch, M., Dahm, S. & Thamm, M. Patterns of sensitization to inhalant and food allergens-findings from the German Health Interview and Examination Survey for Children and Adolescents. Int Arch Allergy Immunol 162, 263-70 (2013).
7. Asarnoj, A. et al. Sensitization to inhalant allergens between 4 and 8 years of age is a dynamic process: results from the BAMSE birth cohort. Clin Exp Allergy 38, 1507-13 (2008).
8. Konieczny, A. et al. The major dog allergens, Can f 1 and Can f 2, are salivary lipocalin proteins: cloning and immunological characterization of the recombinant forms. Immunology 92, 577-86 (1997).
9. Mattsson, L., Lundgren, T., Everberg, H., Larsson, H. & Lidholm, J. Prostatic kallikrein: a new major dog allergen. J Allergy Clin Immunol 123, 362-8 (2009).
10. Curin, M. et al. Microarrayed dog, cat, and horse allergens show weak correlation between allergen-specific IgE and IgG responses. J Allergy Clin Immunol 133, 918-21 (2014).
11. Saarelainen, S. et al. Animal-derived lipocalin allergens exhibit immunoglobulin E cross-reactivity. Clin Exp Allergy 38, 374-81 (2008).
12. Apostolovic, D. et al. The cat lipocalin Fel d 7 and its cross-reactivity with the dog lipocalin Can f 1. Allergy 71, 1490-5 (2016).
13. Asarnoj, A. et al. Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study. J Allergy Clin Immunol 137, 813-21 (2016).
14. Immonen, A. et al. T cell epitope-containing peptides of the major dog allergen Can f 1 as candidates for allergen immunotherapy. J Immunol 175, 3614-20 (2005).
15. Immonen, A. K. et al. Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy. Immunology 120, 38-46 (2007).
16. Bush, R. K. Advances in allergen immunotherapy in 2015. J Allergy Clin Immunol 138, 1284-1291 (2016).
17. Durham, S. R. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341, 468-75 (1999).
18. Larché, M., Akdis, C. A. & Valenta, R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6, 761-71 (2006).
19. Cox, L. Allergy immunotherapy in reducing healthcare cost. Curr Opin Otolaryngol Head Neck Surg 23, 247-54 (2015).
20. Hedlin, G. et al. Immunotherapy with cat-and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 87, 955-64 (1991).
21. Curin, M. et al. Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens. Int Arch Allergy Immunol 154, 258-63 (2011).
22. Valenta, R., Campana, R., Focke-Tejkl, M. & Niederberger, V. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol 137, 351-7 (2016).
23. Focke-Tejkl, M. et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol 135, 1207-17 (2015).
24. Niederberger, V. et al. Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. J Allergy Clin Immunol 136, 1101-3 (2015).
25. Zieglmayer, P. et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine 11, 43-57 (2016).
26. Cornelius, C. et al. Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. EBioMedicine 11, 58-67 (2016).
27. Valenta, R. et al. From allergen genes to allergy vaccines. Annu Rev Immunol 28, 211-41 (2010).
28. Focke-Tejkl, M. et al. Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. J Allergy Clin Immunol 133, 836-45 (2014).
29. Liukko, A. L. et al. Human CD4+ T cell responses to the dog major allergen Can f 1 and its human homologue tear lipocalin resemble each other. PLoS One 9, e98461 (2014).
30. Arnon, R. & Van Regenmortel, M. H. Structural basis of antigenic specificity and design of new vaccines. FASEB J 6, 3265-74 (1992).
31. Focke, M. et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 34, 1525-1533 (2004).
32. Gieras, A. et al. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. J Immunol 186, 5333-44 (2011).
33. Fedorov, A. A., Ball, T., Mahoney, N. M., Valenta, R. & Almo, S. C. The molecular basis for allergen cross-reactivity: crystal structure and IgE-epitope mapping of birch pollen profilin. Structure 5, 33-45 (1997).
34. Valenta, R., Campana, R., Marth, K. & van Hage, M. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 272, 144-57 (2012).
35. Focke, M., Swoboda, I., Marth, K. & Valenta, R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 40, 385-97 (2010).
36. Gieras, A. et al. IgE epitope proximity determines immune complex shape and effector cell activation capacity. J Allergy Clin Immunol 137, 1557-65 (2016).
37. Kamata, Y. et al. Characterization of dog allergens Can f 1 and Can f 2. 2. A comparison of Can f 1 with Can f 2 regarding their biochemical and immunological properties. Int Arch Allergy Immunol 142, 301-8 (2007).
38. Perzanowski, M. S. et al. Relevance of specific IgE antibody titer to the prevalence, severity, and persistence of asthma among 19-year-olds in northern Sweden. J Allergy Clin Immunol 138, 1582-1590 (2016).
39. Curin, M. et al. Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction. Clin Exp Allergy 44, 882-94 (2014).
40. Gasteiger, E. et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The proteomics protocols handbook. 1st ed. Totowa (NJ): Humana Press; p. 571-607 (2005).
41. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. E. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 10, 845-858 (2015).
42. Breustedt, D. A., Korndörfer, I. P., Redl, B. & Skerra, A. The 1.8-A crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J Biol Chem 280, 484-93 (2005).
43. Sanner, M. F., Olson, A. J. & Spehner, J. C. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 38, 305-320 (1996).
44. Pettersen, E. F. et al. UCSF Chimera-A visualization system for exploratory research and analysis. J Comput Chem 25, 1605-1612 (2004).
45. Bendell, C. J. et al. Transient protein-protein interface prediction: datasets, features, algorithms, and the RAD-T predictor. BMC Bioinformatics 15, 82 (2014).
46. Hartl, A., Hochreiter, R., Stepanoska, T., Ferreira, F. & Thalhamer, J. Characterizatio of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a. Allergy 59, 65-73 (2004).